Skip to main content
SpringerLink
Log in

Failure of nomifensine to reduce serum prolactin levels in patients with hepatic encephalopathy

  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

In order to investigate whether the variations in prolactin (PRL) secretion found in patients with liver cirrhosis are related to the derangement of neurotransmitter metabolism, serum PRL levels were measured in 8 patients with hepatic encephalopathy (a condition where neurotransmission is severely deranged), in 10 patients with liver cirrhosis but without encephalopathy and in 10 control subjects under control conditions and in response to nomifensine, levodopa and synthetic TRH administration. Inhibition of endogenous catecholamine reuptake by nomifensine was able to significantly reduce PRL levels in normal subjects and in patients with liver cirrhosis, whereas only one out of 8 patients with hepatic encephalopathy showed a reduction in PRL levels. On the contrary, levodopa administration was able to reduce PRL secretion in all the subjects studied. PRL release by TRH was greater in patients with liver disease than in controls. The results seem to indicate that the derangement in neurotransmitter metabolism which occurs in liver cirrhosis is one, but not the sole cause of alterations of PRL secretion in liver cirrhosis. The failure of nomifensine to depress PRL is an early finding in the course of encephalopathy and may be of diagnostic value.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Horrobin D.H., Phil D., Manku M.S., Massar B.A. Hepatorenal syndrome and prolactin. N. Engl. J. Med. 290: 408, 1974.

    PubMed  CAS  Google Scholar 

  2. Van Thiel D.H., Gavaler J.S., Lester R., Loriaux D.L Braunstein G.D. Plasma estrone, prolactin neurophysin and sex steroid-binding globulin in chronic alcoholic men. Metabolism 24: 1015, 1975.

    Article  PubMed  Google Scholar 

  3. Van Thiel D.H., Gavaler J.S., Sanghvi A. Lack of dissociation of prolactin responses to thyrotropin releasing hormone and metoclopramide in chronic alcoholic men. J. Endocrinol. Invest. 5: 281, 1982.

    Article  PubMed  Google Scholar 

  4. Panerai A.E., Salerno F., Manneschi M., Cocchi D., Muller E.E. Growth hormone and prolactin response to thyrotropin releasing hormone in patients with severe liver disease. J. Clin. Endocrinol. Metab. 45: 134, 1977.

    Article  PubMed  CAS  Google Scholar 

  5. Morgan M.Y., Jacovits A.W., James I.M., Sherlock S. Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy. Gastroenterology 78: 663, 1980.

    PubMed  CAS  Google Scholar 

  6. Borzio M., Caldara R., Ferrari C., Barbieri C., Borzio F., Romussi M. Growth hormone and prolactin secretion in liver cirrhosis: evidence for dopaminergic dysfunction. Acta Endocrinol. (Kbh.) 97: 441, 1981.

    CAS  Google Scholar 

  7. Morgan M.Y. Basal and dynamic prolactin secretion in liver disease. In: Langer M., Chiandussi L., Chopra I.J., Martini L. (Eds.), The endocrines and the liver. Academic Press, London, 1982, p.

    Google Scholar 

  8. Bauer A.G.C., DeGreef W.J., De Jong F.H., Wilson J.H.P., Lamberts S.W.J. Hyperprolactinemia of portal hypertension in rats. Gastroenterology 82: 179, 1982.

    PubMed  CAS  Google Scholar 

  9. Van Thiel D.H., Lester R. Further evidence for hypothalamic-pituitary dysfunctions in alcoholic men. Clin. Exp. Res. 2: 344, 1978.

    Article  Google Scholar 

  10. Van Thiel D.H., McClain J.C., Elson M.K., Lester R. Evidence for autonomous secretion of prolactin in some alcoholic men with cirrhosis and gynecomastia. Metabolism 27: 1178, 1978.

    Google Scholar 

  11. Fisher J.R., Baldessarini R.J. False neurotransmitters in hepatic failure. Lancet 1: 75, 1971.

    Article  Google Scholar 

  12. Munro H.N., Fernstrom J.D., Wurtman R.J. Insulin, plasma amino acid imbalance and hepatic coma. Lancet 1: 722, 1975.

    Article  PubMed  CAS  Google Scholar 

  13. Zieve L., Olsen R. Can hepatic coma be caused by a reduction of brain noradrenaline or dopamine? Gut 78: 688, 1977.

    Article  Google Scholar 

  14. Guilleret G., Pomier-Layrargues G., Pons F., Cadilhac J., Michel H. Changes in brain catecholamine levels in human cirrhotic hepatic encephalopathy. Gut 21: 565, 1980.

    Article  Google Scholar 

  15. Hunt P., Kannengiesser M.H., Raynaud J.P. Nomifensine: a new potent inhibitor of dopamine re-uptake into synaptosomes from rat brain corpus striatum. J. Pharm. Pharmacol. 26: 370, 1974.

    Article  PubMed  CAS  Google Scholar 

  16. Algeri S., Ponzio F., Achilli G., Perego C. Biochemical effect of nomifensine in catecholaminergic systems: in vivo studies. In: Costa E., Racagni G. (Eds.), Typical and atypical antidepressants. Raven Press, New York, 1982, p. 208.

    Google Scholar 

  17. Braestrup C., Scheel-Kruger J. Methylphenidate-like effect of the new antidepressant drug nomifensine (HOE 984) Eur. J. Pharmacol. 38: 305, 1976.

    Article  PubMed  CAS  Google Scholar 

  18. M’Uller E.E., Genazzani A.R., Murru S. Nomifensine: diagnostic test in hyperprolactinemia states. J. Clin. Endocrinol. Metab. 47: 1352, 1978.

    Article  Google Scholar 

  19. Masala A., Alagna S., Devilla L., Delitala G., Rovasio P.P. Inhibition of prolactin secretion by nomifensine in man. Clin. Endocrinol. (Oxf;) 12: 237, 1980.

    Article  CAS  Google Scholar 

  20. Dallabonzana D., Spelta B., Botalla L., Oppizzi G., Silve-strini F., Chiodini P.G., Liuzzi A. Effects of nomifensine on growth hormone and prolactin secretion in normal subjects and in pathological hyperprolactinemia. J. Clin. Endocrinol. Metab. 54: 1125, 1982.

    Article  PubMed  CAS  Google Scholar 

  21. Sherlock S. Hepatic pre-coma and coma. In: Sherlock S. (Ed.), Diseases of the liver and biliary system. Blackwell Scientific Publications, Oxford, 1975, p. 84.

    Google Scholar 

  22. Moriondo P., Travaglini P., Nissim M., Faglia G. Evaluation of two inhibitory tests (Nomifensine and L-Dopa + Carbidopa) for the diagnosis of hyperprolactinemia states. Clin. Endocrinol. (Oxf.) 13: 525, 1980.

    Article  CAS  Google Scholar 

  23. Wernze H., Schmitze A. Plasma prolactin and prolactin release in liver cirrhosis. Acta Hepatogastroenterol. 24: 97, 1977.

    CAS  Google Scholar 

  24. Van Thiel D.H., Lester R. Alcoholism: its effect on hypothalamic-pituitary-gonadal function. Gastroenterology 71: 318, 1976.

    PubMed  Google Scholar 

  25. McClain C.J., Kromhout J.P., Elson M.K., Van Thiel D.H. Hyperprolactinemia in portal systemic encephalopathy. Dig. Dis. Sci. 26: 353, 1981.

    Article  PubMed  CAS  Google Scholar 

  26. Zanoboni A., Zanoboni-Muciaccia W. Elevated basal growth hormone and growth hormone response to thyrotropin releasing hormone in alcoholic patients with cirrhosis. J. Clin. Endocrinol. Metab. 45: 626, 1977.

    Google Scholar 

  27. Sandford J., Gala R.R. The influence of oestrogen administration in vivo on in vitro prolactin release. Acta Endocrinol. (Kbh.) 92: 437, 1979.

    Google Scholar 

  28. Lloyd H.M., Meares J.D., Jacobi J. Effects of oestrogen and bromocriptine on in vivo secretion and mitosis in prolactin cells. Nature 255: 497, 1975.

    Article  PubMed  CAS  Google Scholar 

  29. Raymond V., Beaulieu M., Labrie F. Potent antidopaminergic activity of estradiol at the pituitary level on prolactin release. Science 200: 1173, 1978.

    Article  PubMed  CAS  Google Scholar 

  30. Bratusch-Marrain P. Björkman O., Waldhausl W., Wahren J. Hepatic disposal of endogenous growth hormone and prolactin in man. Eur. J. Clin. Invest. 9: 257, 1979.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituto di Patologia Medica, Viale San Pietro 12, 07100, Sassari, Italy

    A. Masala, S. Alagna, P. P. Rovasio, A. Deplano, L. Chiandussi &  M. Langer

  2. Istituto di Farmacologia, University of Sassari, Via Rolando 1, 07100, Sassari, Italy

    V. Anania

Authors
  1. A. Masala
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Alagna
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. P. Rovasio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Deplano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. Anania
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L. Chiandussi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Langer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Masala, A., Alagna, S., Rovasio, P.P. et al. Failure of nomifensine to reduce serum prolactin levels in patients with hepatic encephalopathy. J Endocrinol Invest 8, 25–29 (1985). https://doi.org/10.1007/BF03350631

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03350631

Key-words

Search

Navigation